Saxagliptin / Metformin (4) – Komboglyze®

Diabetes mellitus type 2, combination therapy other than insulin and sulphonylurea

Characteristics

Start date 01.08.2017 – Marketing authorisation: 26.06.2017
Resolution 01.02.2018
INN Saxagliptin/Metformin
Brand name Komboglyze®
Pharm. company AstraZeneca GmbH
G-BA Procedure ID D-306
ATC code A10BD10 Combinations of oral blood glucose lowering drugs (A10BD)
DDD 2 U O
Therapeutic area Metabolic diseases
Reason for procedure New therapeutic indication
Specialty ACT change

Studies and Results

  • Clinical trials
    • The G-BA commissioned the IQWiG to assess the dossier.

Patients whose blood glucose levels are not adequately controlled by treatment with at least two blood glucose-lowering medicinal products (excluding insulin and sulphonylureas), in addition to diet and exercise

  • An additional benefit is not proven.
  • The pharmaceutical manufacturer has not provided any data for the assessment of the additional benefit of saxagliptin/metformin in combination with other medicinal products for the treatment of diabetes (excluding insulin and sulphonylureas) compared with the appropriate comparator therapy.

Courtesy translation only, please refer to the German original.

Associated procedures



<< List of all resolutions